B7.1/NHS76: A new costimulator fusion protein for the immunotherapy of solid tumors

Journal of Immunotherapy

Volumn 29, Issue 4, 2006, Pages 425-435

  Liu, Aihong ^a   Hu, Peisheng ^a   Khawli, Leslie A ^a   Epstein, Alan L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

B7.1; Costimulator; Fusion protein; Treg cells; Tumor necrosis therapy

Indexed keywords

ANTIBODY; ANTIGEN; CD25 ANTIBODY; CD4 ANTIBODY; CYTOTOXIC ANTIBODY; FUSION PROTEIN B7 1 NHS76; HYBRID PROTEIN; IMMUNOSTIMULATING AGENT; MONOCLONAL ANTIBODY; REGULATORY T LYMPHOCYTE ANTIBODY; T LYMPHOCYTE ANTIBODY; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; COLON CANCER; CONTROLLED STUDY; DRUG ANTIGENICITY; DRUG BINDING; DRUG EFFICACY; EXPERIMENTAL MOUSE; FEMALE; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; KIDNEY CANCER; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; TUMOR REGRESSION; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY AFFINITY; ANTIGENS, CD28; ANTIGENS, CD80; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS; RECOMBINANT FUSION PROTEINS;

EID: 33747881482     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000208260.80791.3d     Document Type: Article

References (40)

1. Foss FM. Immunologic mechanisms of anti-tumor activity. Semin Oncol. 2002;29(Suppl 7):5-11.
2. Zheng P, Sarma S, Guo Y, et al. Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: lessons from recurrent tumors. Cancer Res. 1999;59:3461-3467.
3. Abken H, Hombach A, Heuser C, et al. Tuning tumor-specific T-cell activation: a matter of co-stimulation? Trends Immunol. 2002;23:240-245.
4. Linsley PS, Brady W, Grosmaire L, et al. Binding of the B cell activation antigen B7 to CD28 co-stimulates T cell proliferation and interleukin-2 mRNA accumulation. J Exp Med. 1999;173:721-730.
5. Freedman AS, Freeman G, Horowitz JC, et al. B7, a B-cell restricted antigen that identifies preactivated B cells. J Immunol. 1985;139:3260-3267.
6. Gordon J, Freeman AS, Freedman JM, et al. B7, A new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol. 1989;143:2714-2722.
7. Freeman GJ, Gribben JG, Boussiotis VA, et al. Cloning of B7-2: a CTLA-4 counter-receptor that co-stimulates human T cell proliferation. Science. 1993;262:909-911.
8. Hathcock KS, Laszlo G, Pucillo C, et al. Comparative analysis of B7-1 and B7-2 co-stimulatory ligands: expression and function. J Exp Med. 1994;180:631-640.
9. Hodge JW, Abrams S, Schlom J, et al. Induction of anti-tumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 co-stimulatory molecules. Cancer Res. 1994;54:5552-5555.
10. Townsend SE, Su FW, Atherton JM, et al. Specificity and longevity of anti-tumor immune responses induced by B7-transfected tumors. Cancer Res. 1994;54:6477-6483.
11. + T cells by B7-transfected melanoma cells. Science. 1993;259:368-370.
12. Travis J. A stimulating new approach to cancer treatment. Science. 1993;259:310-311.
13. McHugh RS, Ahmed SN, Wang YC, et al. Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7.1 (CD80). Proc Natl Acad Sci USA. 1995;92:8059-8063.
14. Singh NP, Yolcu ES, Taylor DD, et al. A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity. Cancer Res. 2003;6:4067-4073.
15. Hoffmann P, Mueller N, Shively JE, et al. Fusion proteins of B7.1 and a carcinoembryonic antigen (CEA)-specific antibody fragment opsonize CDA-expressing tumor cells and coactivate T-cell immunity. Int J Cancer. 2001;92:725-732.
16. Challita-Eid PM, Penichet ML, Shin SU, et al. A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell co-stimulatory pathway. J Immunol. 1998;160:3419-3426.
17. Epstein AL, Chen FM, Taylor CR. A novel method for the detection of necrotic lesions in human cancers. Cancer Res. 1988;48:5842-5848.
18. Chen FM, Taylor CR, Epstein AL. Tumor necrosis treatment of ME-180 human cervical carcinoma model with 131I-labeled TNT-1 monoclonal antibody. Cancer Res. 1989;49:4578-4585.
19. Sharifi J, Khawli LA, Hu P, et al. Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors. Hybridoma Hybridomics. 2001;20:305-311.
20. Hornick JL, Sharifi J, Khawli LA, et al. A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors. Cancer Biother Radiopharm. 1998;13:255-268.
21. Hu P, Hornick JL, Glasky MS, et al. A chimeric Lym-1/interleukin-2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake. Cancer Res. 1996;56:4998-5004.
22. 2, a fully human vasopermeability enhancing agent to increase the uptake and efficacy of cancer chemotherapy. Clin Cancer Res. 2005;11:3084-3093.
23. Frankel ME, Gerhard W. The rapid determination of binding constants for antiviral antibodies by a radioimmunoassay. An analysis of the interaction between hybridoma proteins and influenza virus. Mol Immunol. 1979;16:101-106.
24. Lyons AB. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods. 2000;243:147-154.
25. Gross JA, Callas E, Allison JP. Identification and distribution of the co-stimulatory receptor CD28 in the mouse. J Immunol. 1992;149:380-388.
26. Gerstmayer B, Hoffmann M, Altenschmidt U, et al. Co-stimulation of T-cell proliferation by a chimeric B7-antibody fusion protein. Cancer Immunol Immunother. 1997;45:156-158.
27. + T cells to cause regression of an advanced lymphoma. J Immunol. 1990;71:90-95.
28. Onizuka S, Tawara I, Shimizu J, et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor a) monoclonal antibody. Cancer Res. 1999;59:3128-3133.
29. Gavallo F, Martin-Fontecha A, Bellone M, et al. Co-expression of B7.1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur J Immunol. 1995;25:1154-1162.
30. Chen L, Ashe S, Grody WA, et al. Co-stimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992;71:1093-1102.
31. Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 co-stimulation on T cell-mediated tumor immunity. J Exp Med. 1994;179:523-532.
32. Yang G, Hellstrom KE, Hellstrom I, et al. Antitumor immunity elicited by tumor cells transfected with B7.2, a second ligand for CD28/CTLA-4 co-stimulatory molecules. J Immunol. 1995;154:2794-2800.
33. Philip R, Clary B, Grunette-Eilinski L, et al. Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer. Clin Cancer Res. 1996;2:59-68.
34. Tolba KA, Bowers WJ, Hilchey SP, et al. Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia. Blood. 2001;98:287-295.
35. Pfeifer A, Verma IM. Gene therapy: promises and problems. Annu Rev Genom Hum Genet. 2001;2:177-211.
36. Li J, Hu P, Khawli LA, et al. LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors. J Immunother. 2003;26:320-331.
37. + T-cell depletion. Clin Cancer Res. 2003;63:8384-8392.
38. Schwartz JD, Zhang X, Nathenson SG, et al. Structural mechanisms of costimulation. Nat Immunol. 2002;3:427-434.
39. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734-1736.
40. Croft M, Bradley LM, Swain SL. Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol. 1994;152:2675-2685.